Strategies to eliminate cancer stem cells: Clinical implications
- 30 June 2006
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (9), 1293-1297
- https://doi.org/10.1016/j.ejca.2006.01.045
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpBlood, 2004
- Discontinuation of imatinib therapy after achieving a molecular responseBlood, 2004
- Goals and Objectives in the Management of Metastatic Breast CancerThe Oncologist, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBlood, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Leukemic stem cells: where have they gone wrong?Blood, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001